Efficacy, Safety, and Tolerability of NBI-1065890 in Adults with Tardive Dyskinesia

2 1

What is this study about?

The study focuses on adults with Tardive Dyskinesia, a condition that causes repeated, involuntary movements of the face, tongue, or other body parts. The investigational drug being tested is an oral capsule containing NBI-1065890. Participants will receive either this capsule or a matching placebo capsule that looks the same but does not contain active medicine.

The purpose of the study is to determine whether the investigational drug reduces the severity of the movements compared with the placebo. Participants will be randomly assigned to one of the two groups and will take the assigned capsule each day for about eight weeks, with regular clinic visits to record any changes and to monitor safety.

Effectiveness will be assessed using the Abnormal Involuntary Movement Scale (AIMS), a video‑based rating that scores the level of involuntary movements, and the Clinical Global Impression – Improvement (CGI-I), a simple overall rating of how much a person’s condition has improved. Both scales are reviewed by experts who do not know which treatment was given. Safety checks, such as blood tests and reports of side effects, will also be performed throughout the study.

1 randomization

after you join the study, you will be assigned by a computer to receive either the test medication or a matching placebo. the assignment is double‑blind, which means neither you nor the study staff will know which one you receive.

2 baseline assessment

before you start taking any study medication, a series of measurements will be taken to record the severity of your tardive dyskinesia. this includes a video recording that will be evaluated with the abnormal involuntary movement scale (aims) and a clinical global impression of improvement (cgi‑i) rating. these results serve as the reference point for later comparisons.

3 start of study medication

you will begin taking one hard gelatin capsule by mouth each day. the capsule may contain the test drug nbi‑1065890 or a matching placebo powder, depending on your randomization. the exact dose is not specified in the study information, but the capsule is taken daily for the entire 8‑week treatment period.

4 regular monitoring visits

throughout the 8‑week treatment period, you will attend scheduled visits (in person or remotely) to check for side effects, ensure the medication is being taken as directed, and collect any additional safety information. these visits help the study team monitor your health while you remain blinded to the treatment you receive.

5 week 8 assessment

at the end of week 8, the same evaluations performed at baseline will be repeated. a new video will be recorded and scored with the aims scale, and a clinician will assign a cgi‑i rating to determine any change in your condition. these results are used to assess the effectiveness of the test medication compared with placebo.

6 final visit and end of treatment

after the week 8 assessment, you will stop taking the study capsule. a final safety check will be performed to record any remaining side effects or concerns. the study medication period is considered complete at this point.

Who Can Join the Study?

Be an adult (age 18 years or older) who can take part in the study.
Have a doctor‑confirmed diagnosis of one of these mental health conditions: schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder (MDD), and have had the diagnosis for at least three months before screening.
Have a doctor‑confirmed diagnosis of tardive dyskinesia (TD) that was caused by medicines called neuroleptics (antipsychotic drugs), and have had TD for at least three months before screening.
Show a moderate or severe level of TD, measured by the Abnormal Involuntary Movement Scale (AIMS). The total AIMS score (items 1‑7) must be 6 or higher, and the overall movement severity (item 8) must be judged as moderate or severe by a video reviewer who does not know which treatment you receive.
Be willing to have video recordings of your movement assessment reviewed by a certified, blinded rater.
Both men and women are eligible to join the study.
People who are considered “vulnerable” (for example, those who may have limited ability to protect their own interests) may participate if they meet all other criteria.

Who Cannot Join the Study?

Having Parkinson‑like movement problems (known as parkinsonism) or noticeable extra movement side effects, as shown by a score higher than allowed on a movement‑assessment test (Modified Simpson‑Angus Scale).
Scoring 2 or more on a test that measures feeling restless or unable to sit still (Barnes Akathisia Rating Scale).
Scoring 50 or more on a questionnaire that evaluates overall mental health symptoms (Brief Psychiatric Rating Scale).
Being hospitalized for schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder (MDD) within the last six months.
Having a medical condition that is not stable or a chronic disease that is currently getting worse.
Having any past history of neuroleptic malignant syndrome, a serious reaction to certain psychiatric medicines.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country
A-Shine s.r.o.	Plzen	Czechia
NEUROPIX-AGPSMPP OOD	Sofia	Bulgaria
Medical Center Detsko Zdrave EOOD	Sofia	Bulgaria
Msmkv Bbxol Dfwgmjlt nfavfioonrap aeuicnkvsj svfmgb	Banska Bystrica	Slovakia
Ehllvm sbvgzs	Kosice	Slovakia
Bxkjqhtfallzhpgaf sbqnkf	Kladno	Czechia
Nxbukxzshgouhiqsvg srdydg	Prazske Predmesti	Czechia
Kvwugksbp sisbwn	Dubnica nad Váhom	Slovakia
Nkphujuxs S Prxavrmrgbbb Peyxoyrvl Sa Sntvne V Btqfifvqxo	Bojnice	Slovakia
Drd Ihc Natipw Olqpnqvgtx Cjbdmu Flq Iuilafkrzt Pvdlstyd Fwg Sizkgxxnpul Mvfwfjt Cinp Id Pwipdnlsxc Eb	Cherven Bryag	Bulgaria
Sqksq Pzbofbcmjne Hxluveqp Ssf Iaaw Rrppfd &hqpxgm Njrt Igbic	Novi Iskar	Bulgaria
Udkffamlps Mxgeusqzkkgg Hbtiicgw Fsb Ajuzzw Tywagvtgz Skbhr Gessbn Efd	Plovdiv	Bulgaria
&xxrqmihqmngn Hathna Cteqsj – Vxlyqz Tlfmfsaaapyxre Echza Votdib Thwtgsu	Veliko Tirnovo	Bulgaria
Dnrmseitjylvynnzlzzbuee Cwyntc Mqtzcww M Vvaeb Oat	Varna	Bulgaria
Mstltfi Cmmspw Siqfpqk Plerssa Eclo	Plovdiv	Bulgaria
Uhcfl &rpavzj Paviy Dud Ssnmjr Kezdstncu Ay	Stara Zagora	Bulgaria

Trial status

Country	Status	Recruitment Start
Bulgaria	Not yet recruiting	01.10.2026
Czechia	Not yet recruiting	01.10.2026
Slovakia	Not yet recruiting	01.10.2026

Trial locations

NBI-1065890 is an experimental medicine being tested as a possible treatment for tardive dyskinesia, a movement disorder that can occur after long‑term use of certain drugs. In this study participants take the medicine in a hard gelatin capsule taken by mouth. Researchers are looking to see if the drug can reduce the involuntary movements, and they are also monitoring how safe and well‑tolerated it is compared with a placebo.

Investigated Diseases:

Tardive dyskinesia

Tardive Dyskinesia – Tardive dyskinesia is a movement disorder that develops after prolonged exposure to certain dopamine‑blocking drugs. It is characterized by repetitive, involuntary movements, most often affecting the lips, tongue, and facial muscles. Over time, the movements can spread to the arms, legs, and trunk. The abnormal movements may become more frequent or intense with continued medication use. Even after the triggering drug is stopped, the movements can persist and may change slowly over months or years.

Trial ID:

2025-524104-30-00

Protocol code:

NBI-1065890-TD2033

NCT ID:

NCT07365462

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Efficacy, Safety, and Tolerability of NBI-1065890 in Adults with Tardive Dyskinesia

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?